Abstract | A new paradigm has emerged for osteogenesis imperfecta as a collagen-related disorder. The more prevalent autosomal dominant forms of osteogenesis imperfecta are caused by primary defects in type I collagen, whereas autosomal recessive forms are caused by deficiency of proteins which interact with type I procollagen for post-translational modification and/or folding. Factors that contribute to the mechanism of dominant osteogenesis imperfecta include intracellular stress, disruption of interactions between collagen and noncollagenous proteins, compromised matrix structure, abnormal cell-cell and cellmatrix interactions and tissue mineralization. Recessive osteogenesis imperfecta is caused by deficiency of any of the three components of the collagen prolyl 3-hydroxylation complex. Absence of 3-hydroxylation is associated with increased modification of the collagen helix, consistent with delayed collagen folding. Other causes of recessive osteogenesis imperfecta include deficiency of the collagen chaperones FKBP10 or Serpin H1. Murine models are crucial to uncovering the common pathways in dominant and recessive osteogenesis imperfecta bone dysplasia. Clinical management of osteogenesis imperfecta is multidisciplinary, encompassing substantial progress in physical rehabilitation and surgical procedures, management of hearing, dental and pulmonary abnormalities, as well as drugs, such as bisphosphonates and recombinant human growth hormone. Novel treatments using cell therapy or new drug regimens hold promise for the future.
Introduction
Osteogenesis imperfecta, also known as 'brittle bone disease' , is a clinically heterogeneous heritable connective tissue disorder, the causative defects of which are directly related to type I collagen, including abnormalities of collagen primary structure and insufficient protein quantity, post-translational modification, folding, intracellular transport or matrix incorporation. The clinical features of osteogenesis imperfecta commonly include low bone mass and reduced bone material strength, which result in bone fragility and suscepti bility to fracture, bone deformity and growth deficiency. In its various types, it occurs in approximately 1 in 15,000-20,000 births, 1 with mostly autosomal dominant inheritance. Over 1,500 dominant mutations in either COL1A1 or COL1A2, which encode the α-chains α1(I) and α2(I) of type I collagen (Box 1), have been identified. 2 Type I collagen is formed from procollagen-a heterotrimer composed of two proα1(I) and one proα2(I) chains, in which the helical collagen region is flanked by globular pro-domains at both the amino and carboxyl termini ( Figure 1 ). The amino acid glycine is obligatory at every third helical residue (Gly-X-Y sequence) because of spatial constraints inside the triple helix. 3 Procollagen is extensively hydroxylated and glycosylated post-translationally (Box 1). 4 Mutations that cause dominant osteogenesis imperfecta alter the structure or quantity of type I collagen and cause a skeletal phenotype that ranges from subclinical to lethal.
Recessive osteogenesis imperfecta with lethal to moderate phenotypes is caused by defects in genes whose products interact with type I collagen. Most recessive cases have null mutations in genes that encode proteins involved in collagen prolyl 3-hydroxylation (CRTAP, LEPRE1 and PPIB) [5] [6] [7] [8] [9] [10] or those responsible for correct helical folding (FKBP10 and SERPINH1). 11, 12 Human cases and murine models of osteogenesis imperfecta are providing insight into common pathways in dominant and recessive osteogenesis imperfecta, leading to the re-evaluation of its definition, classification and therapeutic approaches.
Classification of osteogenesis imperfecta
The original classification by Sillence in 1979 divided osteogenesis imperfecta into types on the basis of clinical, radiographic and genetic criteria. 13, 14 Although proposed before collagen defects were identified in osteogenesis imperfecta, it remains useful in an updated form which accounts for new gene defects or distinctive histomorphometry ( Table 1 ). The classification discussed in this Review and elsewhere 15 attributes the original four Sillence types entirely to mutations in COL1A1 or COL1A2. The phenotype of null COL1A1 alleles and mild helical substitutions may overlap. We propose that type I osteogenesis imperfecta should be limited to cases with type I collagen haploinsufficiency, including those indivi duals in whom haploinsufficiency produces a moderate clinical outcome. The rare indivi dual with a collagen structural mutation and a very mild phenotype should be designated as having type IV osteogenesis imperfecta. This classification would ensure that type I osteogenesis imperfecta is a clinically and bio chemically homogenous grouping, as well as the only dominant osteogenesis imperfecta form in which structurally abnormal collagen is not present.
Moreover, recessive osteogenesis imperfecta types are also separated based on the gene in which the mutation occurs and the general function of the gene product (collagen prolyl 3-hydroxylation, collagen chaperone). This classification succinctly communicates the genetic defect and general phenotypic severity, while also generating homogenous groupings for therapeutic approaches and basic investigations of disease mechanism. Several versions of an alternative classification have been proposed, in which the recessive types are incorporated into the original Sillence numeration based on clinical phenotype; 16, 17 these classifications vary depending on whether the histologically defined types V and VI are retained or also classified clinically. However, this alternative classifica tion results in children with defects in the same gene (for example, LEPRE1) being clas sified as having different types of osteogenesis imperfecta because of variability in clinical features. As a result, individuals with lethal LEPRE1 mutations would be designated as having type II osteogenesis imperfecta, whereas survivors with severe disease would be classified as having type III. This definition could confuse genetic counseling and is, therefore, not recommendable. that include bone fragility and deformity, as well as short stature, hearing loss and dentinogenesis imperfectawhich causes teeth discoloration and translucency and predisposes to tooth decay and breakage. Blue or grey sclerae and extrasutural, wormian bones are frequent, albeit not uniform, findings. In addition, the features of individuals with different types of osteogenesis imperfecta may overlap.
Osteogenesis imperfecta type I, the mildest form, has a triad of features: fractures, blue sclerae and hearing loss. Fractures often begin with ambulation and decrease after puberty. These individuals have minimal bone deformity,
Box 1 | Formation and modification of collagen
COL1A1 and COL1A2 transcripts are translated in the endoplasmic reticulum into proα1(I) and proα2(I) chains, which consist of a central left-handed triple helical domain (1,014 amino acids) flanked by globular domains. The C-terminal noncollagenous domain of the proα chains contains interchain disulfide bonds and is important for the correct alignment and assembly of the heterotrimer formed of two proα1(I) and one proα2(I) chains. 213 This process is supported by interactions with endoplasmic reticulum-resident molecular chaperones, such as immunoglobulin-heavy-chain binding protein (GRP78), Serpin H1 and the prolyl 3-hydroxylation complex. 89, 214, 215 Proper folding of the triple helical domain from C-terminus to N-terminus in the assembled trimer requires the presence of a glycine residue at every third amino acid because of steric constraints in the interior of the helix. Until the chains become inaccessible, the helical portions of the collagen chains undergo post-translational modifications, including prolyl 4-hydroxylation and lysyl hydroxylation, catalyzed by L-proline trans-4-hydroxylase (P4H) and lysyl hydroxylase, respectively, followed by hydroxylysyl glycosylation, which is catalyzed by glucosyl-galactosyl transferases. Specific proline residues, α1(I)Pro986 and α2(I)Pro707, are fully or partially 3-hydroxylated by the prolyl 3-hydroxylation complex, which consists of cartilage-associated protein (CRTAP), prolyl 3-hydroxylase 1 (P3H1) and peptidyl prolyl cis-trans isomerase B (PPIB; also known as cyclophilin B). After procollagen is secreted into the pericellular space, the terminal propeptides are removed by specific proteinases. 4 The mature triple helical collagen molecules participate in a higher order structure in the extracellular matrix, the heterotypic fibril. Collagen fibrils are stabilized by formation of covalent crosslinks between the telopeptides and adjacent domains of collagen molecules. Fibrils interact with noncollagenous proteins, bind soluble factors such as growth factors and cytokines and constitute the scaffold for mineral deposition. Figure 1 | Mechanisms contributing to autosomal dominant osteogenesis imperfecta bone dysplasia: from mutant type I collagen gene to bone defect. Mutations in either COL1A1 or COL1A2 are translated into collagen α-chains with abnormal structure, which delay folding of the heterotrimer and result in excess post-translational modification of the collagen helical region. Mutant procollagen chains unable to incorporate into heterotrimers are retrotranslocated into the cytosol and degraded by the ERAD pathway (1); fully misfolded heterotrimers with structural defects generate supramolecular aggregates that are eliminated by autophagy (2); mutant molecules with triple helical mutations are degraded through an unidentified pathway (3). Finally, abnormal procollagen can be secreted, processed and incorporated in the extracellular matrix (4) . The secreted mutant collagen affects fibril structure and interactions of noncollagenous proteins with matrix, as well as matrix mineralization and osteoblast development and cell-cell and cell-matrix crosstalk. The overall result is bone deformity and fragility, although the relative importance of various contributions is under investigation. Abbreviations: ERAD, endoplasmic reticulum-associated proteasomal degradation; NCP , noncollagenous proteins.
near normal stature and rarely have dentinogenesis imperfecta. Osteogenesis imperfecta type II is perinatally lethal. Affected infants have short, bowed long bones with crumpling from in utero fractures, blue or grey sclerae and a large, soft cranium. Radiographs reveal undertubulated long bones. The most common cause of death is respiratory failure, associated with small thorax, rib fractures, pneumonia and perhaps with intrinsic collagen-related abnormalities of lung tissue. 18, 19 Type III or progressivedeforming osteogenesis imperfecta is the most severe, nonlethal form. Affected indivi duals may sustain hundreds of fractures. Most have triangular facies, frontal bossing, blue or grey sclerae, dentino genesis imperfecta, vertebral compressions and scoliosis. Many have platybasia (malformation of the skull base due to softening of the skull, with bulging upward of the floor of the posterior cranial fossa) or basilar invagination. These patients have extremely short stature; about half exhibit 'popcorn' forma tion (sclerotic lines seen on radiographs that represent growth plate fragmentation) at femoral growth plates. 20 The moderately severe osteogenesis imperfecta type IV has a broad phenotypic range that overlaps with types I and III. Affected indivi duals incur dozens of long bone fractures, but most achieve ambulation. Scleral hue, dentinogenesis imperfecta, basilar impression, hearing loss and final stature are variable.
Disease etiology
Almost all cases of dominant osteogenesis imperfecta have low bone mass and increased skeletal fragility. 21 Histomorphometry of iliac crests from patients with osteogenesis imperfecta revealed decreased trabecular and cancellous bone volume, increased osteoblast and osteoclast surface and an overall increase in bone forma tion rate per bone surface. However, deposition of new bone at the single osteoblast level (mineral apposition rate) is reduced and is not compensated for by the increased cell number. 22 Interestingly, Fourier transform infrared spectroscopy (FTIR) and quantitative backscattered electron imaging both revealed elevated bone matrix mineralization. These data support the occurrence of a common bone defect in patients with osteogenesis imperfecta that is downstream from the collagen quanti tative and qualitative mutations. This defect alters bone cell function and the remodeling mechanisms which normally maintain bone homeostasis. [22] [23] [24] The mechanism of autosomal dominant osteogenesis imperfecta encompasses the gene mutation, the resulting collagen alteration and dysfunction at the extracellular matrix and at tissue levels ( Figure 1 ). The composition and organization of the bone matrix influences the presence of growth factors and cytokines important for prolifera tion and differentiation of bone cells, 25 as well as matrix mineralization, which confers bone stiffness. A variety of murine models have aided the investigation of the pathogenic mechanism that underlies dominant osteogenesis imperfecta (Table 2) , implicating elevated osteoclast function, 26, 27 variability of expression, [28] [29] [30] endoplasmic reticulum stress 31, 32 and apoptosis, 32 as well as providing new targets for therapy.
33-35
Gene and protein defects The type I collagen biosynthetic pathway has been extensively reviewed 36 and a brief description is provided in Box 1. The matrix insufficiency of type I osteogenesis imperfecta results from a premature termination codon in the COL1A1 transcript, which activates a cellular mRNA surveillance mechanism termed nonsensemediated decay (NMD). This process reduces mutant transcripts, leading to the synthesis of half of the amount of normal collagen protein. Complete absence of the α1(I) chain is not compatible with life, as demonstrated by the embryonic lethality of the homozygous Mov13 mice, a mouse model created by the insertion of the murine Moloney leukemia virus into the first intron of the Col1a1 gene ( Table 2) . 37 Homozygous null mutations in COL1A2 lead to a range of phenotypes. Those associated with NMD and loss-of-function lead to assembly of α1(I) homo trimers. Clinically, formation of homotrimers causes mild Ehlers-Danlos syndrome, with hypermobility in childhood and cardiac valve disease in adulthood, rather than osteogenesis imperfecta. 38 By contrast, the homozygous Oim mouse, which harbors a naturally occurring Col1a2 mutation (Table 2) , as well as a patient with osteogenesis imperfecta 39 due to a deletion in the α2(I) C-propeptide, did not show activation of NMD. Both in animals and humans, normal levels of COL1A2 transcripts are produced, which are translated into α2(I) chains that cannot incorporate into collagen. Given that α1(I) homotrimer formation alone does not lead to osteogenesis imperfecta, the intracellular accumulation of mutant α2(I) chains may cause the skeletal dysplasia. Types II-IV osteogenesis imperfecta are caused by defects in type I collagen structure, most commonly glycine substitutions (80%) and splice site mutations (20%). 2 Glycine substitutions delay helix folding, leading to post-translational overmodification (Box 1), which may compromise secretion and/or processing of collagen. 2, 40 The Osteogenesis Imperfecta Mutation Consortium, an international collaboration of laboratories that characterize osteogenesis imperfecta mutations, identified substitutions at ~44% of glycine residues. 2 Substituting residues may disrupt noncovalent bonds, which causes local unwinding of the triple helix. In both α-chains, substitutions in the N-terminus are not lethal ( Figure 2) . Overall, 36% of COL1A1 glycine substitutions had a lethal outcome, especially those with charged or branched side chains. Substitutions in the major ligand-binding regions MLBR2 and MLBR3 of α1(I) are exclusively lethal, which suggests that interactions of collagen with noncollagenous proteins in the matrix are essential to bone formation ( Figure 2 ). 2 Although the over modification gradient does not correlate with clinical severity in α1(I), empirical rules 41 correctly assign most lethal or non-lethal outcomes. In addition, the overmodification of structurally normal collagen in recessive osteogenesis imperfecta raises the possibility that excess hydroxylation and glycosylation have a direct detrimental role on the extracellular matrix. Most COL1A2 glycine substitutions are not lethal (81%). The 121 Baek et al.
212
Abbreviations: ENU, N-ethyl-N-nitrosourea; M-MuLV, Moloney murine leukemia virus; +/-, heterozygous for the mutation; -/-, homozygous for the mutation.
REVIEWS α2(I) lethal substitutions occur in eight regularly spaced clusters that align with proteoglycan binding sites in the collagen fibril ( Figure 2 ). 2, 42, 43 The different patterns of lethality in α1(I) and α2(I) indicate each chain has a differ ent role in matrix organization. Also, substitutions at over 40 glycine residues result in both lethal and nonlethal forms of osteogenesis imperfecta, 2 supporting the importance of phenotype-modifying factors. 28, 29 Comparison of phenotypes in patients with either quantitative or structural collagen changes found higher lumbar spine areal BMD, greater cortical width and lower bone turnover parameters in patients with type I osteogenesis imperfecta than in indivi duals with types III or IV. 24 However, BMD and histo morphometry of patients with nonlethal osteogenesis imperfecta did not correlate with the α-chain containing the mutation, the mutation location in the chain or the substituting residue, which suggests that other factors are crucial for outcome severity.
Rare mutations that affect procollagen processing sites or the chain register lead to distinctive variants of osteogenesis imperfecta. The procollagen N-propeptides and C-propeptides are cleaved by specific propeptidases in the pericellular space (Box 1). Glycine substitutions in the first 90 residues of the α1(I) helical region disrupt a stable N-anchor domain and prevent or delay N-propeptide removal. The pN-collagen (procollagen from which the C-propeptide has been removed) is incorporated into the matrix, decreases fibril size and causes a phenotype with characteristics of both osteogenesis imperfecta and Ehlers-Danlos syndrome. 44, 45 Disruption of N-propeptide processing by helical defects in α2(I) also leads to this phenotype. [46] [47] [48] [49] [50] For C-propeptide processing, substitutions at the aspartate-alanine cleavage site residues result in mild osteogenesis imperfecta with increases in vertebral DXA Z scores and bone mineralization that are counterintuitive for osteogenesis imperfecta, due to accelerated mineralization. 51 Substitutions in the proα1(I) or proα2(I) C-propeptide have broad phenotypic variability, causing types II-IV osteo genesis imperfecta; the majority of cases are either mild or lethal. [52] [53] [54] [55] Given that α-chains align at the C-terminal end, these mutations delay chain incorporation and helix formation. However, the C-propeptide is not normally incorporated into collagen fibrils, leaving the mechanism of these osteogenesis imperfecta cases unclear.
Small triplet deletion or duplication mutations shift the register of α-chains in the helix. Although the Gly-X-Y sequence is maintained, salt bridges are disrupted by misalignment of X and Y residues between chains. These cases are severe or lethal and have delayed collagen folding. 56, 57 The register shift can propagate to the end of the helix and affect N-propeptide cleavage. Interestingly, substitutions at the Y-position may also propagate a regi ster shift nearly the full length of the collagen helix, which interferes with N-propeptide processing and causes variable phenotypes, including mild osteo genesis imperfecta, hyperextensibility and Caffey disease, a transient infantile cortical hyperostosis. [58] [59] [60] Several pedigrees with autosomal dominant Caffey disease have been shown to have the same COL1A1 Y-position change (p.Arg1014Cys) associated with selfresolving inflammation and sub periosteal new bone formation with reduced penetrance in infancy. [60] [61] [62] The hyperostosis may be the consequence of the disruption of binding of a ligand such as inter leukin 2 to collagen, which may cause increased susceptibility to periosteal injury during infancy. 60 
Intracellular stress
Misfolded collagen chains in the endoplasmic reticulum activate the unfolded protein response, which triggers synthesis of chaperones to assist collagen folding or, alternatively, increases protein degradation. 63 The cellular response varies depending on the type of collagen mutation ( Figure 1 ). Collagen with triple helical mutations is removed by autophagy, as are collagen aggregates in cells that lack Serpin H1. 64 In calvarial osteoblasts from Aga2 mice, which harbor a Col1a1 mutation induced by N-ethyl-N-nitrosourea (ENU), retention of mutant collagen in the endoplasmic reticulum increases expression of chaperones GRP78 and Serpin H1, the apoptosis-inducing transcription factor CHOP (also known as DDIT-3 or GADD153) and activation of caspase-3-dependent apoptosis. 32 Brtl mice carry a Gly349Cys mutation in one Col1a1 allele. Most heterozygous offspring have a moderate type IV osteogenesis imperfecta phenotype, although perinatal lethality is seen in 30% of Brtl pups. In calvaria of lethal Brtl pups, relative intracellular retention of helices with one mutant chain 31 is associated with increased expression of CHOP but normal GRP78 expression, which suggests that collagen misfolding activates the unfolded protein response through a GRP78-independent response. 28 Finally, C-propeptide mutations that impair trimer assembly result in increased GRP78 expression, retrotranslocation of the misfolded proα chains into the cytosol and degradation via the proteasomal endoplasmic reticulum-associated degradation pathway. 65, 66 Extracellular matrix and mineralization In osteogenesis imperfecta types II-IV, the mixture of normal and mutant α-chains results in matrix heterogeneity and may contribute to the generally greater severity of α1(I) defects, as heterozygous α1(I) defects yield helices with two, one or no mutant chains, whereas α2(I) defects result in two helix compositions. In Brtl mice, homozygosity for the mutant allele leads to matrix homogeneity and, unexpectedly, to a less severe pheno type, which suggests that this feature affects bone properties. 67 The association of lethal osteogenesis imperfecta with mutations in MLBRs in α1(I) monomers or proteoglycan binding sites on fibrils for α2(I) 2, 42, 43 potentially reflects compromised interactions of noncollagenous proteins with fibrils ( Figure 2 ). The noncollagenous protein composition of the matrix is altered secondarily in osteogenesis imperfecta, which may also affect bone properties. Cultured osteoblasts from patients with osteogenesis imperfecta synthesize reduced amounts of osteonectin and proteoglycans and increased amounts of fibronectin, thrombospondin and hyaluronan. 68, 69 Thrombospondin and decorin bind growth factors, whereas decorin and fibronectin are important for fibrillogenesis.
The normal D-period spacing of fibrils generates gap and overlap regions that are important for mineral nucleation and collagen crosslinks and noncollagenous protein interactions, respectively. 43 In the bone matrix of heterozygous Brtl mice, the collagen fibril D-period has significantly greater variability in spacing than in wildtype littermates. 70 The abnormal structure of heterotypic fibrils could affect the type and amount of mineral deposited by increasing the density of nucleation sites. 71, 72 The matrix in patients with osteogenesis imperfecta also contains abnormal levels of noncollagenous proteins known to regulate crystal deposition and growth. 73, 74 Elevated bone mineral content has been demonstrated by FTIR and BMD distribution in bone with quantitative and structural defects of collagen and is also found in murine models. 72, 75 The elevated mineral content and loss of mineralization heterogeneity contribute to the bone fragility in patients with osteogenesis imperfecta, 76, 77 possibly through loss of ductility.
Cell-cell and cell-matrix interactions
Cellular interactions with abnormal matrix and compromised osteoblast development influence signaling between osteoblasts and osteoclasts, which increases bone remodeling and exacerbates the bone weakness caused by the primary collagen change (Figure 1 ). Osteoblasts sense osteocyte apoptosis via gap junctions and receive negative feedback from osteocytes through sclerostin. 78, 79 Osteoblasts then trigger osteoclast maturation and recruitment. 78 Ultrastructural examination of bone samples from patients with osteogenesis imperfecta revealed increased numbers of osteocytes and multiple osteocytes in some lacunae. 80 In the Brtl mouse, osteoclast numbers are elevated in femora, uncoupled from osteoblast numbers. Osteoclast precursors from bone marrow of Brtl mice are larger, more numerous and more intensely stained for tartrate-resistant acid phosphatase compared with wild-type mice. 26 The RANKL/ OPG ratio, which is indicative of osteoblast-stimulated osteoclast differentiation, is normal in Brtl bone, so other soluble factors triggered by the abnormal matrix may increase osteoclast development. In the homozygous Oim mouse, a higher RANKL/OPG ratio and increased TNF expression were detected in sorted immature osteoblasts compared with wild-type mice, which supports cell-cell signaling as a key aspect of elevated bone turnover in osteogenesis imperfecta. 27 Crosslinks in collagen fibrils are important for the maturation of osteoblast precursors. 81 In osteogenesis imperfecta, collagen located at the surface of fibrils had fewer crosslinks than in the fibril interior. 82 Contact with crosslink-deficient matrix by bone cell populations could contribute to impaired osteoblast maturation and increased osteoclast recruitment in osteogenesis imperfecta. Also, the effects of collagen heterogeneity in dominant osteogenesis imperfecta could be mediated in part by abnormal crosslinking.
Recessive osteogenesis imperfecta
Including the three genes that encode the components of the collagen 3-hydroxylation complex, six genes have now been implicated in recessive osteogenesis imperfecta (Table 1) . Collectively, they account for 2-5% of cases of osteogenesis imperfecta detected in North America and Europe. 6, 41 Other genes remain to be identified, including mutations in the gene responsible for type V osteogenesis imperfecta.
The collagen 3-hydroxylation complex Prolyl 3-hydroxylase 1 (P3H1), cartilage-associated protein (CRTAP) and peptidyl-prolyl cis-trans isomerase B (PPIB, also known as cyclophilin B) assemble into a 1:1:1 complex within the endoplasmic reticulum that post-translationally modifies specific proline residues in unfolded collagen α-chains. 83 These modifications include nearly complete 3-hydroxylation of Pro986 residues of α1(I), α1(II) and α2(V) collagen chains, plus several partially modified sites in α2(I) (80% Pro707), α1(II), α1(V) and α2(V) chains. 84 The complex also has a chaperone function. Furthermore, each complex component is a multifunctional protein with independent extracellular functions. [85] [86] [87] The importance of the complex and α1(I) Pro986 hydroxylation for bone development became apparent when the recessive bone defect in the Crtap -/-knockout mouse 5 converged with the chromosomal location of type VII osteogenesis imperfecta (3p22-24.1) 88 and with a biochemical approach to recessive osteogenesis imperfecta based on overmodification of structurally normal collagen (Figure 3) . 89 Cartilage-associated protein CRTAP, the helper protein of the complex, is highly homologous to the amino end of P3H1, but lacks the C-terminal catalytic domain. 86, 89, 90 CRTAP is expressed in the skeletal system by chondrocytes, osteoblasts and osteoclasts. Although mainly localized in the endoplasmic reticulum, it is also secreted and might have a matrix function. 5, 86, 91 The Crtap -/-mouse has a moderately severe connective tissue disorder characterized by rhizomelia (shortened proximal segment of limbs), kyphosis (curvature of the spine in an anterior-posterior plane), growth deficiency and osteopenia (Table 2) . 5, 92 In humans, CRTAP deficiency (type VII osteogenesis imperfecta) presents as a moderate to lethal recessive osteo chondrodystrophy, with growth deficiency and rhizomelia as in the mouse, and also with white sclerae, severe osteo porosis with neonatal fractures and broad undertubulated long bones. 5, 6 Almost all reported CRTAP mutations cause frameshifts that result in NMD and absence of the CRTAP protein, with loss of α1(I) 3-hydroxylation. 91 Our group had hypothesized that severe osteogenesis imperfecta with collagen overmodification but without a collagen structural defect would be caused by defects in one or more proteins that interact with collagen. However, it was not anticipated that loss of Pro986 3-hydroxylation or defects in members of the 3-hydroxylation complex such as CRTAP would delay type I collagen folding (Figure 3) . Prolyl 3-hydroxylase 1 P3H1, the enzymatic component of the complex, is encoded by LEPRE1. P3H1 is the only complex component that contains a KDEL sequence for endoplasmic reticulum retrieval. This KDEL-containing isoform is crucial for collagen modification. 93 A P3H1 isoform is also secreted as the chondroitin sulfate proteo glycan leprecan. 87 P3H1 expression is localized to tissues rich in fibrillar collagens, which are abundant during develop ment. 94 Molecular defects in LEPRE1 (type VIII osteogenesis imperfecta), most of which lead to reduced transcripts, were identified shortly after CRTAP mutations 7,10,93 and found to outnumber type VII osteo genesis imperfecta cases. Type VIII osteo genesis imperfecta patients present with severe to lethal osteogenesis imperfecta, white sclerae, rhizomelia and under tubulation of long bones. Those who survive into childhood have extremely low BMD, severe growth deficiency and bulbous metaphyses. A LEPRE1 founder mutation (c.1080+1G>T), found in West Africans and African Americans, occurs in almost half of type VIII osteo genesis imperfecta cases reported. 95 In type VIII, as in type VII osteogenesis imperfecta, Pro986 3-hydroxylation of α1(I) is absent and the collagen helical region is over modified, supporting delayed folding ( Figure 3 ). The Lepre1 null mouse has a milder phenotype than humans with type VIII osteogenesis imperfecta, although they share growth deficiency, rhizomelia, reduced BMD, abnormal hypertrophic chondrocytes and delayed secretion of over modified collagen from cultured cells ( Table 2) . 96 
Peptidyl-prolyl cis-trans isomerase B
The third component of the collagen 3-hydroxylation complex, PPIB, is a peptidyl-prolyl cis-trans isomerase. Isomerization of the naturally occurring cis proline to the trans conformation is rate-limiting for collagen folding. 97 PPIB was thought to be the only collagen isomerase. 98 Several mutations in PPIB (type IX osteogenesis imperfecta) 9 ,99 create premature stop codons or misfolded proteins and cause severe to lethal osteogenesis imperfecta. The resulting phenotype and overmodified collagen biochemistry are similar to that of osteogenesis imperfecta types VII and VIII, except without rhizomelia, consistent with a dysfunctional 3-hydroxylation complex. By contrast, our group identified a PPIB mutation (c.26T>C, pre viously referred to as c.2T>C
6 ) in siblings with moderate osteogenesis imperfecta and white sclerae but without rhizomelia. 8 This mutation occurs at position Met9 of the protein sequence as predicted by the NIH genetic sequence database GenBank® (US Department of Health and Human Services. Bethesda, MD). However, it was unproven whether Met1 or Met9 was the initiation codon, and Met1 is not fully conserved evolutionarily. Our data support the occurrence of this mutation in the start codon, given that PPIB transcripts were reduced and the protein was completely absent-despite the use of multiple antibodies in Western blot analysis of guanidinium extracts or after proteasomal inhibition-as expected for an initiator mutation. 100 P3H1 and CRTAP levels are one-third and two-thirds of normal levels in PPIB-null cells, which indicates that PPIB enhances complex stability. However, activity of the complex in the absence of PPIB is sufficient to normally 3-hydroxylate α1(I) Pro986. 8 Furthermore, normal helical modification Media Cell C o n t r o l C R T A P -n u ll L E P R E 1 -n u ll P P IB -n u ll C o n t r o l C o n t r o l C R T A P -n u ll L E P R E 1 -n u ll P P IB -n u ll C o n t r o l α1(I) α2(I) Figure 3 | Electrophoretic analysis of type I collagen synthesized by dermal fibroblasts with mutations in genes coding for collagen 3-hydroxylation complex components. Most mutations in CRTAP, LEPRE1 or PPIB cause decreased or absent protein due to nonsense mediated decay. Both [ 3 H]-proline-labelled collagen alpha chains are fully overmodified in media and cell layer from primary fibroblast cultures of osteogenesis imperfecta patients with CRTAP or LEPRE1 null mutations, indicating delayed folding of the collagen helix. However, in the fibroblasts of siblings with a mutated PPIB start codon, the secreted α-chains have normal electrophoretic migration and collagen in the cell layer fraction has minimal backstreaking of α1(I).
in the absence of PPIB (Figure 3) , suggestive of normal folding, argues for redundancy of collagen cis-trans isomerases in human cells.
A Ppib -/-knockout mouse with an out-of-frame exon 2/4 junction has nonlethal recessive osteogenesis imperfecta with reduced bone volume, kyphosis and growth deficiency ( Table 2) . 101 Ppib transcripts are reduced and the protein is undetectable, but murine collagen biochemistry differs from both human stop and start codon mutations. Collagen gel electrophoretic migration had a delayed baseline rather than a broadened band as in human cases with mutations that cause premature termina tion codons; helical modification was not quantitated in the mouse. Pro986 3-hydroxylation was absent in murine collagen, although partial persistence of complex components in murine tissue is suggested by detection of reduced levels of P3H1. Functionally, procollagen remained in the endoplasmic reticulum and was not properly transported into the Golgi. The differences in collagen modification between the knockout mouse and the human start codon mutation may reflect alternative binding partners supporting P3H1-CRTAP stability in humans or redundancy of cis-trans isomerases.
Pathogenesis of 3-hydroxylation defects
Both P3H1 and CRTAP are absent or severely reduced in cells that lack either LEPRE1 or CRTAP, although transcript levels of the respective normal gene are somewhat increased. Transfection of null cells with constructs encoding the absent transcript restore both proteins to detectable levels. 102 These data indicate that CRTAP and P3H1 are mutually protective in the 3-hydroxylation complex and explain the overlapping phenotypes of patients with types VII and VIII osteogenesis imperfecta. LEPRE1-null or CRTAP-null cells lack the complex chaperone function, as well as collagen 3-hydroxylation. Absence of the P3H1-CRTAP complex also abrogates the collagen chaperone and isomerase functions of PPIB, 101 although cellular levels of PPIB are unaffected. 102 Similarly, binding of misfolded PPIB to P3H1-CRTAP appears to interfere with complex function, whereas P3H1-CRTAP can bind and modify collagen in the total absence of PPIB. 8, 9 Crucial questions remain concerning the enzymatic and chaperone functions of the complex. Ishikawa et al. 85 showed that the complex contains collagen chaperone as well as isomerase activity. Dysregulation of the complex may eliminate 3-hydroxylation, but loss of complex collagen chaperone and isomerase functions may dominate the disease mechanism. PPIB loses its ability to bind gelatin without CRTAP-P3H1, and knockdown of P3H1 severely reduces the ability of PPIB to bind nascent collagen chains in vitro. 101 One case of osteogenesis imperfecta type IX in which the P3H1-CRTAP complex was able to normally 3-hydroxylate collagen in the total absence of PPIB resulted in normal collagen folding and a moderate phenotype. 8 The mechanism by which deficiency of the 3-hydroxyla tion complex leads to collagen overmodification remains to be elucidated. Pro986 3-hydroxylation minimally affects collagen stability. 103 Although collagen folding has not been measured directly in these cases, overmodification is an established consequence of slow folding. 40 However, the extent of Pro986 hydroxylation does not correlate with overmodification or pheno type; patients with 0-5% Pro986 hydroxylation have the same helical overmodification and lethal outcome as those with 25% Pro986 hydroxylation. 91 Another possible contribution to the mechanism of osteogenesis imperfecta is a proposed role for the 3-hydroxylation modification in the extracellular matrix. Weis et al. 84 suggested that 3-hydroxproline sites function in fibril assembly through intermolecular hydrogen bonding. Deficiency of type V collagen 3-hydroxylation could also affect formation of heterotypic fibrils. Alternatively, the 3-hydroxylation modification may not be crucial per se but could serve as a binding epitope for noncollagenous proteins involved in mineralization. 84 Furthermore, absence of 3-hydroxylation complex components has a metabolic aspect, with intracellular effects beyond collagen hydroxylation. Mutant fibroblasts appear stellate and foamy in culture (J. C. Marini, unpublished work). The absence of complex chaperone activity would be expected to cause endoplasmic reticulum stress and ultimately apoptosis. We found a surprising increase in collagen secretion in LEPRE1-null fibroblasts, which points to a possible role for P3H1 in the regulation of proline metabolism or collagen synthesis. 7 Type VI osteogenesis imperfecta Individuals with type VI osteogenesis imperfecta have a severe skeletal phenotype with a distinctive and defining feature in their bone histomorphometry. Under polarized light microscopy, normal orientation of lamellae is lost; instead, a 'fish-scale' pattern is often seen. Evidence exists for a severe mineralization defect. 104 Truncating mutations in SERPINF1, which encodes pigment epitheliumderived factor (PEDF), were identified in three probands with severe recessive osteogenesis imperfecta, using whole-exome sequencing. 105 Post-translational modification and secretion of type I collagen was reported to be normal in these patients. SERPINF1 has now been identified as the causative gene in type VI osteogenesis imperfecta by use of homo zygosity mapping for candidate gene regions, followed by next-generation sequencing of these regions, in patients with a diagnostic bone biopsy (B. Lee and F. H. Glorieux, personal communica tion). Knockout of the Serpinf1 gene in mice results in vascular and epithelial abnormalities, but no bone pheno type was reported. 106 Collagen chaperone defects Absence or dysfunction of the collagen chaperones Ser pin H1 and FKBP10 has been reported to cause reces sive osteogenesis imperfecta types X and XI, respectively.
11,12
Serpin H1 Serpin H1 is an endoplasmic reticulum-resident collagenspecific chaperone that binds to and accompanies the assembled procollagen molecule together with PPIB into the Golgi.
107 Serpinh1 -/-mice are embryonically lethal, which demonstrates that Serpin H1 is required for normal development. 108 Serpinh1 defects caused intra cellular aggregation and delayed secretion of collagen, with abnormal fibrils; type IV collagen misfolding disrupted basement membranes. 64, 109, 110 Severe bone dysplasia in canine and human cases (type X osteogenesis imperfecta) is associated with SERPINH1 missense mutations. 12, 111 Dachshunds with a missense mutation that causes osteogenesis imperfecta with dentino genesis imperfecta (c.977C>T, p.Lys326Pro) survived post natally, probably due to residual Serpin H1 protein levels. 111 The only child reported with Serpin H1 deficiency was homo zygous for the missense mutation c.233T>C, p.Leu78Pro. The patient had a severe osteogenesis imperfecta phenotype, including blue sclerae and dentino genesis imperfecta. Atypical features included transient skin bullae, pyloric stenosis and renal stones requiring nephrectomy. 12 The mutant transcript was stable, but protea somal degradation led to minimal Serpin H1 protein. Although collagen secretion was somewhat delayed, the amount of secreted total collagen was normal in culture, with unaltered post-translational modification, which indicates independence of the Serpin H1 chaperone function and 3-hydroxylation. However, types I and III collagen had increased sensi tivity to protease digestion in vitro, suggesting that Serpin H1 monitors triple helix folding and stabilizes the collagen helix during transit through the secretory pathway.
FKBP10
The peptidyl-prolyl cis-trans isomerase FKBP10 (previously known as FKBP65) is localized in the endoplasmic reticulum and has chaperone activity for collagen.
112 FKBP10 frameshift mutations (type XI osteogenesis imperfecta) were first reported in Turkish and Mexican patients. 11 All probands have deforming osteogenesis imperfecta including long bone fractures, ligamentous laxity, platyspondyly and scoliosis, although sclerae and teeth are normal. Biochemically, normal collagen 3-hydroxylation, without evidence of increased helical modification, was reported. FKBP10 mutations were associated with delayed collagen secretion and a dilated endoplasmic reticulum. Consistent with a defect in the FKBP chaperone activity, intracellular aggregates of collagen were demonstrated. In one case, bone histology with an abnormal lamellar pattern was reported, with elevated alkaline phosphatase levels in two indivi duals with the Turkish frameshift mutation. 11 Emerging data indicates that the phenotypic spectrum of mutations in FKBP10 overlaps with Bruck syndrome 1, an autosomal recessive condition characterized by osteoporosis, joint contractures at birth, fragile bones and short stature, which is often thought of as 'osteogenesis imperfecta with congenital joint contractures' . 113 In a family from Saudi Arabia, siblings have symptoms of Bruck syndrome caused by an FKBP10 exon 6 frameshift mutation that alters the third peptidyl-prolyl cis-trans isomerase domain. 114 However, an exon 5 frameshift mutation, (c.831_832insC), predicted to lead to a premature stop codon downstream of the third isomerase domain, has been detected in five pedigrees reflecting four ethnic groups, 115 including the Mexican family in the original report, 11 which was not noted to have contractures. Three of these five pedigrees had findings of Bruck syndrome, including a sibship with one child diagnosed with type III osteogenesis imperfecta and the second with Bruck syndrome. Kelley et al. proposed that FKBP10 mutations were the cause of Bruck syndrome 1, although the map position of FKBP10 (17q21.2) does not co incide with the originally reported chromosomal position of Bruck syndrome 1 based on a single twogeneration Kurdish family (17p12). 115, 116 Although the 17p12 region contained the largest contiguous region of homozygosity by descent in this pedigree, resequencing of the Kurdish family might reveal a causative FKBP10 mutation. 116 It is possible that Bruck syndrome 1 is a subset of type XI osteogenesis imperfecta caused by FKBP10 mutations and that the variable manifestation of contractures in individuals with FKBP10 mutations has been previously interpreted as a distinct condition.
Unclassified and type I collagen disorders
Several osteogenesis imperfecta-like or type I collagenbased disorders have so far not been classified as a type of osteogenesis imperfecta owing to incomplete informa tion. For example, Bruck syndrome 2 is a recessive condition caused by mutations in PLOD2 (3q23-24) which encodes bone-specific collagen telopeptide lysyl hydroyxlase (TLH). 117 Affected individuals are reported to be clinically indistinguishable from those with Bruck syndrome 1. PLOD2 (procollagen-lysine,2-oxoglutarate 5-dioxygenase 2) deficiency 118 results in under hydroxylation of the lysines of the collagen telopeptide, but not the triple helix, leading to abnormal collagen crosslinking.
Caffey disease is also a distinctive syndrome, some cases of which are caused by a COL1A1 p.Arg1014Cys substitution. 60 The collagen matrix defect causes symptoms of osteogenesis imperfecta and Ehlers-Danlos syndrome, whereas the partially penetrant cortical hyperostosis is limited to infancy.
Another osteogenesis imperfecta-like condition is caused by a homozygous genetic defect in SP7 (also known as osterix), a zinc-finger transcription factor. 119, 120 Osterix mutations might be expected to cause devastating defects of osteoblast differentiation. Sp7-null mice are perinatally lethal with loss of both endochondral and intramembraneous bone formation and reduced expression of the osteoblast-specific markers Col1a1, BSP, osteonectin and osteopontin. 121 An Egyptian child with a frameshift mutation in SP7 that leads to loss of the zinc-finger domain important for DNA binding has a moderately severe osteogenesis imperfecta-like phenotype with decreased vertebral DXA. 119 Classification of this defect is premature in the absence of biochemical, cellular or bone data, given that SP7 does not have a selective direct effect on type I collagen.
Clinical aspects of osteogenesis imperfecta

Secondary features of osteogenesis imperfecta
Hearing Hearing loss is a common secondary feature of osteogenesis imperfecta, which affects some individuals with all Sillence types of osteogenesis imperfecta. 122 Generally a progressive disorder, hearing loss is often a mixture of conductive and sensorineural deficiency, mostly bilateral, and commonly manifests in the second to fourth decades of life. Nonetheless, about 5% of children with osteogenesis imperfecta have been reported to have hearing loss of 20 dB. 123 By 50 years of age, about half of patients have subjective hearing loss in a Scottish survey, 124 whereas over 60% of Finnish adults with osteogenesis imperfecta had hearing loss on audio metry in a population study. 125 In this population, patients of all osteogenesis imperfecta types had hearing loss (approximately 60%, 80% and 40% for types I, III and IV, respectively). Further analysis of the Finnish population showed no correlation of hearing loss with collagen mutation type (null allele, glycine substitution or splicing defect) or mutated collagen gene, and a lack of penetrance in some family members. 126 About half of the Finnish adults with osteogenesis imperfecta also had vestibular dysfunction, with vertigo generally secon dary to inner ear pathology. 127 The hearing loss in osteogenesis imperfecta is clinically otosclerosis-like in that both result in footplate fixation, although the two conditions are distinct. When amplifica tion is not adequate, surgical options may be indicated. Several large series of stapedectomies reported hearing gains of more than 20 dB in over 80% of operated ears, as well as improved bone conduction thresholds. [128] [129] [130] A second, Dutch series 131 reported success in restoring hearing in patients with type I osteogenesis imperfecta but loss of hearing in a type III case, whereas a Swedish series, 132 encompassing multiple surgeons in different hospital settings, reported more cautious gains, with worsening of hearing loss in 21% of operated ears. For carefully selected patients with profound sensori neural hearing loss, cochlear implantation is an option. 133 The procedure is more challenging due to hyper vascularity of the middle ear mucosa, but results similar to other sensorineural causes were obtained in most of the 10 cases reported. 133 
Dental abnormalities
Dental abnormalities (opalescent teeth, obliterated pulp cavities, and constricted coronal-radicular junctions) were proposed as distinguishing genetic features of osteogenesis imperfecta even before the Sillence classification, with almost complete penetrance in those pedigrees in which it occurred, and were subsequently described as Sillence subtypes A and B (with and without dentinogenesis imperfecta, respectively). 134 Dental examinations with panoramic radiographs revealed 40-80% of children with types III and IV osteogenesis imperfecta had dentinogenesis imperfecta in primary dentition; [135] [136] [137] microscopy suggests very mild dentinogenesis imperfecta may be missed radiographically. 138 Children with yellowish-brown discoloration had more enamel fractures and attrition than those with opalescent grey discoloration and were more likely to need full-mouth restoration with crowns; 135 however, discoloration was not related to the type of osteo genesis imperfecta. 137 Dentinogenesis imperfecta always improved in permanent teeth. A high incidence of malocclusion, impaction and both delayed and accelerated tooth eruption were also noted. Interestingly, the majority of patients with quantitative collagen defects did not have dentinogenesis imperfecta, 139 whereas dentino genesis imperfecta was not associated with any particular molecular abnormalities in patients with altered collagen structure. 139, 140 Expression of Col1a1 in odontoblasts from homozygous Mov13 mice suggests regulation of collagen expression may differ in teeth, 141 which could underlie inconsistencies in the manifestation of dentinogenesis imperfecta. Histology reveals structurally abnormal dentin, with collagen hyperfibers and vesicles. 142 Reduced number and size variation of dentinal tubules were found on scanning electron microscopy of affected teeth, with an abnormally smooth dentin-enamel junction. 143 Microscopic and ultrastructural studies found occluded tubules, some with retrocurved processes and occlusion of the pulp chamber, consistent with odontoblast dysfunction. 144 
Neurological features
Various neurological features are associated with osteogenesis imperfecta, including macrocephaly, hydrocephalus, syringomyelia and basilar invagination (an infolding of the skull base that leads to brainstem distortion). 145 Relative and absolute macrocephaly is common in patients with osteogenesis imperfecta caused by collagen structural defects. Basilar invagination that progresses to brain stem impingement is relatively rare, but its consequences are potentially devastating; progression should be followed with MRI. 146 Early intervention with occipitocervical bracing can delay progression in most cases. 147 Reducible basilar invagination (40%) is treated with posterior fossa decompression and occipitocervical fusion, whereas irreducible basilar invagination (60%) is treated with transoral-transpalatopharyngeal decompression. Despite successful decompression, 80% of basilar invagination progresses within 6 years after surgery. 146 
Growth
Short stature is one of the cardinal features of osteogenesis imperfecta. Endocrine evaluation of the growth axis was normal in most patients with collagen defects; however, about 50% of children had a blunted response to the IGF-1 stimulation test. 148 About half of children with type IV osteogenesis imperfecta treated with recombi nant human growth hormone double their baseline growth rate in the first year of treatment. 149 Given the chondro-osseus manifestations of recessive osteogenesis imperfecta, it is reasonable to speculate that the short stature of dominant osteogenesis imperfecta may be related to abnormalities at the transition from ca rtilage to bone.
Morbidity and mortality
Pulmonary features
Extraskeletal manifestations of osteogenesis imperfecta in the respiratory and cardiovascular systems are the most common causes of morbidity and mortality. 18, 150 Recurrent pneumonia is well-known in children with severe osteogenesis imperfecta, as is right-sided heart failure (cor pulmonale) in adults with severe disease. 1 These effects have been considered secondary to skeletal changes, 18, 150 such as scoliosis, rib fractures or thoracic cage deformity. 18, 21, 151 Individuals with osteogenesis imperfecta and scoliosis >60° have a striking decline of pulmonary function. 151 The presence of severe restrictive lung disease with minimal scoliosis raised the possi bility that bone-independent pulmonary pathology also contributes substantially to morbidity in those with types III and IV osteogenesis imperfecta. 151 Two case studies of osteogenesis imperfecta with lung hypoplasia add to the possible direct role of mutant collagen in lung pathology. 19, 152 Cor pulmonale is considered a late effect of pulmonary dysfunction in osteo genesis imperfecta. 18 Pulmonary function data in patients with structurally abnormal collagen but without scoliosis, as well as data from both dominant and recessive murine models, is needed to delineate the mechanism of pulmonary pathology.
Cardiovascular features
Cardiovascular findings, including valvular insufficiency, aortic root dilatation, atrial septal defects and septal and posterior left ventricular wall thickening have been reported in patients with osteogenesis imperfecta. 153 In adults, aortic root dilatation is the most frequent valvular manifestation. 153, 154 When aortic regurgitation occurs, it is more commonly due to abnormal valvular structure than dilatation of the root. 154 Examination of asymptomatic osteogenesis imperfecta adults by 12-lead electrocardiogram and 2D echocardiography revealed valvular regurgitation in 95%, with tricuspid and mitral regurgitation with or without aortic regurgitation accounting for 60% of cases, and impaired diastolic function. 155 These changes may reflect greater stiffness of myocardial tissue, which may be primary effects of the mutant collagen.
Management of osteogenesis imperfecta
Rehabilitation and physical therapy The goal of physical rehabilitation is to maximize the patient's gross motor function and daily life competencies. This aim is especially important in childhood, when the fundamentals of life functioning are established, and for older individuals, who will experience combined osteogenesis imperfecta and aging effects. Upper arm function, mobility and annual fracture and surgery rates, but not pain, were reported to correlate with DXA Z scores in 20 patients with types I, III and IV osteogenesis imperfecta. 156 The researchers make the reverse inference that improving DXA scores will improve function, but this conclusion is not correct, especially for gross motor skills, and may be a simple correlation of baseline DXA and osteogenesis imperfecta severity. 157, 158 Scoliosis and chest wall deformity also correlate with overall measures of physical health. 151 Furthermore, early onset of scoliosis correlates with reduced mean DXA Z scores and the achievement of motor milestones at a later age. 159 However, children with mild bone disease and hyper laxity of paraspinal ligaments may also develop early aggressive scoliosis, despite moderate DXA Z scores and earlier achievement of gross motor milestones. 58 Physical rehabilitation of children at major clinical centers for osteogenesis imperfecta is individualized and actively promotes increased strength and mobility. Functional tests such as the BAMF (brief assessment of motor function), 160 the GMFM (gross motor function measure; originally designed for cerebral palsey) 161 and the Bleck score 162 have been validated for osteogenesis imperfecta. Muscle strength is scored using consistent criteria individual to each center. The results of rehabilitation have been best documented for the Dutch pediatric osteogenesis imperfecta population. A 4-year follow-up of 5-19-year-olds showed that joint range of motion decreased significantly over time in those with type I osteogenesis imperfecta, especially in the lower extremities, whereas types III and IV patients had severe motion limitations that did not change with time. 163 Children with all types of osteo genesis imperfecta increased selfcare and social function over time, but mobility level plateaued in types III and IV, with muscle strength as the best predictor of ambulation. Children with type I osteogenesis imperfecta had no pulmonary or cardiac defects at rest, 164 whereas reduced exercise tolerance and muscle strength in those with types III or IV contributed to fatigue during activities of daily living. Children with types I and IV osteo genesis imperfecta who participated in a low-resistance physical training program had improved peak oxygen consumption, maximal working capacity and muscle strength after 3 months, but the improvements diminished 6 months after program completion, 165 suggesting that regular exercise of the correct intensity is important to improve fitness. For immobilized children, a pilot study of whole-body vibration using a tilt table in four children with type III or IV osteogenesis imperfecta was reported to achieve upright sitting in two children, and walking with minimal support in two others, which they had not achieved with several years of bisphosphonate therapy. 166 Orthopedic surgery Orthopedic surgery remains a mainstay of lifelong osteogenesis imperfecta management, in a complementary function with physical rehabilitation. Osteotomies of long bones with placement of intramedullary rods are undertaken to correct deformity that impedes function and to manage fracture recurrence. Corrective surgery is often crucial to ambulation. Currently, surgeons have at their disposal two types of telescoping rods-the FassierDuval telescopic intramedullary system and the Sheffield telescopic intramedullary rod, an ammended version of the Dubow-Bailey rod-as well as nonelongating pins, for the immobilization of long bones after osteotomy procedures. Rod migration is a commonly reported complication in osteogenesis imperfecta, 167, 168 occurring more frequently in nontelescoping than in telescoping rods. 169 The Fassier-Duval rods have the advantage of percutaneous placement, minimizing trauma and allowing multiple bones to be treated in one session, followed by early rehabilitation. 170 Flexible nails unload less weight from the bone and are successfully utilized in single or double nail techniques. 171 Non-union occurs in about 15% of osteotomy procedures in osteogenesis imperfecta; 170 the increased incidence of non-union reported after pamidronate treatment may be related to thermal damage from use of an electric saw in that study. 172 The course of the scoliosis that is common in osteogenesis imperfecta is minimally affected by bracing. 173 In Europe, successive use of halo traction followed by spine stabilization can be successful to stabilize and sometimes reduce the curve, improve respiratory function and pain. 174, 175 In contrast to common progression of scoliosis, basilar invagination infrequently progresses to clinically significant compression. 145 To prevent hindbrain herniation and cerebral spinal fluid obstruction, patients may require shunt placement or decompression with occipitocervical fusion 146 to be performed by experi enced surgeons in specialized centers.
Pharmacological therapy
Bisphosphonates are antiresorptive compounds widely administered to children with osteogenesis imperfecta, with the rationale that bones with increased volume of osteogenesis imperfecta-quality matrix will be more fracture resistant. 176, 177 Positive effects on bone histology are obtained from treatment of children with bisphosphonates, including increased trabecular number and cortical thickness; vertebral DXA Z scores increase. 178, 179 Studies in children have shown that these gains are maximized in 2-4 years. 157, 180 Whereas controlled trials concur that bisphosphonates improve vertebral geo metry, 181, 182 the decrease in long bone fractures is equivocal, even in trials with over 125 children. 179, 183, 184 The claims of improved strength, motor function and decreased pain initially reported in observational trials are unsupported by controlled trials. 157 Human and murine studies have raised concerns about high cumulative doses impairing bone modeling and healing, decreasing bone material quality and mineralization heterogeneity and impairing bone cells, 77, 185, 186 but osteonecrosis of the jaw has not been seen in patients with osteogenesis imperfecta. 187 Because bisphosphonates have a decade-plus half-life in bone, it is crucial to determine the lowest effective cumulative dose for improved vertebral geometry. Also, whether children should be treated until epiphyseal closure, to avoid fractures at the junction of treated and untreated bone, needs to be elucidated. 188 Junctional fractures have not been seen on the NIH bisphos phonate regimen; our view is that long-term suppression of bone remodeling is likely to be a greater detriment than junctional fracture.
Two short-acting compounds being investigated in mouse models may be applicable to osteogenesis imperfecta in the future. Denosumab is a fully humanized antibody to RANKL that has antiresorptive action. 189, 190 Inhibition of RANKL will shift the RANKL/OPG ratio and decrease osteoblast signaling, which normally stimu lates 
Box 2 | Common features of dominant and recessive osteogenesis imperfecta
Genetic defects related to collagen structure, modification, folding or processing Overmodification of collagen is a common feature of many collagen structural defects and most 3-hydroxylation defects, apparently as a result of delayed folding, whereas FKBP10 and SERPINH1 defects do not cause overmodification.
Osteochondrodystrophy
Types VII, VIII and IX osteogenesis imperfecta are osteochondrodystrophies. Patients with collagen structural defects or those with FKBP10 mutations have significant growth deficiency, which may represent a defect in transition from cartilage to bone.
Endoplasmic reticulum stress
Collagen defects exhibit a 'swollen' endoplasmic reticulum; increased chronic stress may lead to osteoblast apoptosis. Stress may affect both dominant and recessive forms by impairing osteoblast differentiation or altering cell-cell signaling in bone.
Collagen-protein binding
For structural collagen defects, interactions of noncollagenous proteins with collagen major ligand binding regions and proteoglycan binding sites in matrix may be crucial. The Pro986 3-hydroxylation site may be a binding epitope for proteins involved in mineralization.
Cell-matrix effects
Osteoblasts in contact with abnormal matrix may have increased stress and altered cell-cell signaling caused by collagen heterogeneity or altered modification and fibril disorganization.
Increased bone turnover
Patients with dominant and recessive (types VII and VIII) osteogenesis imperfecta have high bone turnover, with elevated osteoblast and osteoclast surfaces. Studies from murine models point to increased osteoblast-osteoclast signaling, perhaps because immature osteoblasts strongly support osteoclast development from precursors.
Hypermineralization
Bone from patients with osteogenesis imperfecta has decreased areal BMD but elevated matrix mineral content. Bone hypermineralization is a common feature of quantitative or structural collagen defects and of CRTAP defects in mice and patients. Mineralization kinetics may be disrupted by altered noncollagenous protein content in matrix. REVIEWS osteoclast development. Animal studies showed OPG treatment inhibits dental eruption; 191 however, it remains to be determined whether denosumab will have a greater clinical effect on tooth eruption than bisphos phonates, which have been associated with a 1.7-year delay in tooth eruption in 6-14-year-old children and may be longer in those treated since infancy. 192 Anti-sclerostin antibody works by an anabolic pathway to stimulate osteoblast production of matrix 193 and may provide benefit without antiresorptive adverse effects.
Growth hormone has been administered to children with type I, III or IV osteogenesis imperfecta in clinical trials. 149, 194 Although the growth hormone axis is generally normal in children with osteogenesis imperfecta, 148 treatment with standard doses of recombinant human growth hormone can produce significant increases in linear growth. In a study of children with type III or IV osteogenesis imperfecta, about half of the children with type IV doubled their baseline growth rate and maintained increased linear growth over multiple treatment years. They also experienced significant improvement in bone histology and in vertebral DXA. Responders to recombinant human growth hormone had higher baseline type I collagen C-propeptide, a marker for increased matrix production. Similarly, treatment of children with documented COL1A1 quantitative mutations resulted in positive changes in bone histology, muscle mass and strength, as well as improved linear growth. 194 The combina tion of bisphosphonate and recombinant human growth hormone is being tested by several groups, and encouraging results are beginning to emerge. 195 Novel molecular approaches to treatment Potential molecular therapies for osteogenesis imperfecta are modeled on mechanisms of milder disease. Mosaic carrier parents have barely detectable phenotypes, even with high burdens of mutant osteoblasts. 196 Cellular therapy recapitulates the mosaic situation by infusing normal mesenchymal stem cells (MSCs), with osteoblast differentiation potential, into affected individuals. Feasibility studies for MSC therapy were conducted in both humans and mice. Experiments in Brtl and Oim mice showed improved bone properties, despite limited bone engraftment. Transplantation into developing animals yielded the highest donor cell engraftment (<5%), and amelioration of bone structure and integrity. [33] [34] [35] 197, 198 In utero transplantation of whole bone marrow into heterozygous Brtl mice showed that engrafted cells may synthesize a greater amount of normal matrix than the endogenous osteoblasts. 34 Also, MSCs could be used for correction of specific genetic mutations by homologous recombination prior to transplantation. 199, 200 Another approach is allele-specific silencing, which models the null COL1A1 allele. Agents for targeting mutant transcripts include antisense oligonucleotides, ribozymes and siRNA. 201 Ribozymes, in particular, have specificity for single nucleotide changes and have shown positive results in vitro and in culture. 202 Clinical implementation would require the development of appropriate delivery systems. Furthermore, the importance of endoplasmic reticulum stress in osteogenesis imperfecta pathology suggests that strategies addressing protein folding, perhaps by chemical chaperones, [203] [204] [205] may be beneficial.
Conclusions
Exciting developments have generated a new paradigm for osteogenesis imperfecta as a collagen-related disorder. The overlapping features of dominant and recessive osteogenesis imperfecta ( Figure 4 , Box 2) may hold the key to a more complete understanding of the mechanisms underlying this disorder and could in the future provide the basis for more targeted therapeutic approaches.
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